The hollow fiber assay: Continued characterization with novel approaches

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 903-911

  Hall, Leslie Ann M ^a   Krauthauser, Candice M ^a   Wexler, Roseanne S ^a   Hollingshead, Melinda G ^b   Slee, Andrew M ^a   Kerr, Janet S ^a  

^a DUPONT COMPANY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell density; Hollow fiber; Racemic flavopiridol; Western blot analysis; Xenograft

Indexed keywords

CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLAVOPIRIDOL; MITOMYCIN C; POLYVINYLIDENE FLUORIDE; RETINOBLASTOMA PROTEIN; YZ 149;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANES, ARTIFICIAL; MICE; MICE, NUDE; MITOMYCIN; PIPERIDINES; POLYVINYLS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETINOBLASTOMA PROTEIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034009728     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR: in vivo cultivation of tumor cells in hollow fibers. Life Sci 57: 131-141, 1995.
2. Hollingshead M, Plowman J, Alley M, May J, Sausville E: The hollow fiber assay. In: Contrib Oncol-Relevance of Tumor Models for Anticancer Drug Development. Karger Verlag in press.
3. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Tompkins A, Brawley O, Bergan R, Figg WD, Smith A, and Sausville EA: Phase I trial of a novel cyclin-dependent kinase inhihitor flavopiridol in patients with refractory neoplasm. Ann Oncol 7 (Suppl I): 77, 1996.
4. Meijer L: Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 6: 393-397, 1996.
5. Alley MC, Pacula-Cos CM, Hursey ML, Rubinstein LR, Boyd MR: Morphometric and colorimetric analyses of human tumor cell growth and drug sensitivity in soft agar culture. Cancer Res 51: 1247-1256, 1991.
6. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR Jr, Simpson-Herren L, Griswold DP Jr: Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol, Basel, Karger 42: 1-22, 1992.
7. Division of Cancer Treatment, National Cancer Institute. Clinical brochure flavopiridol NSC 649890, NDA 46, 211 1995.
8. Vaisman A, Varchenko M, Said I, Chancy SG: Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27: 54-64, 1997.
9. Wright JE: Phosphoramide and oxazaphosphorine mustards. In: Cancer Therapeutics. Experimental and Clinical Agents. (BA Teicher, ed) Totowa, New Jersey, Humana Press 1997, pp27-39.
10. Giri SD and Chatterjee A: Modulation of mitomycin C-induced sister chromatid exchanges and cell cycle delay by buthionine sulfoximine and reduced glutathione in mouse bone marow cells in vivo. Mutation Research 413: 227-234, 1998.
11. Sedlacek HH, Czech J, Niak R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E: Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9: 1143-1168, 1996.
12. Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, Double JA: Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screerling programs. Cancer Res 58: 5263-5266, 1998.
13. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, Staedel C: Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 78: 454-463, 1998.